Adenoviral gene transfer with soluble vascular endothelial growth factor receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia

Circulation

Volumn 110, Issue 16, 2004, Pages 2424-2429

  Jacobi, Johannes ^a   Tam, Betty Y Y ^a   Wu, Grace ^a   Hoffman, Jana ^a   Cooke, John P ^a   Kuo, Calvin J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Collateral circulation; Genetics; Ischemia; Perfusion

Indexed keywords

ANGIOGENESIS INHIBITOR; DRUG VEHICLE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G2A; PHOSPHATE BUFFERED SALINE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ZK 202650;

ADENOVIRUS GENE TRANSFER; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; FLUORESCENCE; GANGRENE; GROWTH INHIBITION; HISTOPATHOLOGY; LASER DOPPLER FLOWMETRY; LEG ISCHEMIA; LIGAND BINDING; MALE; MOUSE; MUSCLE TISSUE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; TISSUE NECROSIS; TISSUE PERFUSION; VASCULAR DISEASE; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; COLLATERAL CIRCULATION; GANGRENE; GENETIC VECTORS; HINDLIMB; IMMUNOGLOBULIN FC FRAGMENTS; ISCHEMIA; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICE, INBRED C57BL; MICROSPHERES; NECROSIS; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 6444223700     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000145142.85645.EA     Document Type: Article

References (24)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
2. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. VIVA Investigators. Circulation. 2003;107:1359-1365.
3. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108: 1933-1938.
4. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
5. Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol. 2003;23:1143-1151.
6. Deindl E, Buschmann I, Hoefer IE, et al. Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ Res. 2001;89:779-786.
7. Hershey JC, Baskin EP, Corcoran HA, et al. Vascular endothelial growth factor stimulates angiogenesis without improving collateral blood flow following hindlimb ischemia in rabbits. Heart Vessels. 2003;18:142-149.
8. Chang DS, Su H, Tang GL, et al. Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Mol Ther. 2003;7:44-51.
9. Pipp F, Heil M, Issbrucker K, et al. VEGFR-1-selective VEGF homologue PIGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res. 2003;92:378-385.
10. Takeshita S, Pu LQ, Stein LA, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation. 1994;90:228-234.
11. Nagy JA, Vasile E, Feng D, et al. VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol. 2002;67:227-237.
12. Becker CM, Farnebo FA, Iordanescu I, et al. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor flk1. Cancer Biol Ther. 2002;1:548-553.
13. Kuo CJ, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A. 2001;98:4605-4610.
14. Tseng JF, Farnebo FA, Kisker O, et al. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery. 2002;132: 857-865.
15. Lai CM, Brankov M, Zaknich T, et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther. 2001;12:1299-1310.
16. Manual for Using Fluorescent Microspheres to Measure Regional Organ Perfusion. Seattle, Wash: Fluorescent Microsphere Resource Center, University of Washington, Division of Pulmonary and Critical Care Medicine; available at http://www.fmrc.pulmcc.washington.edu.
17. Buckberg GD, Luck JC, Payne DB, et al. Some sources of error in measuring regional blood flow with radioactive microspheres. J Appl Physiol. 1971;31:598-604.
18. Shimpo M, Ikeda U, Maeda Y, et al. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. Cardiovasc Res. 2002;53:993-1001.
19. 121 gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation. 2000;102:565-571.
20. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994; 93:662-670.
21. Hershey JC, Baskin EP, Glass JD, et al. Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis. Cardiovasc Res. 2001;49:618-625.
22. Couffinhal T, Silver M, Zheng LP, et al. Mouse model of angiogenesis. Am J Pathol. 1998;152:1667-1679.
23. Babiak A, Schumm AM, Wangler C, et al. Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion. Cardiovasc Res. 2004;61:789-795.
24. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.